Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05566002 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

Study acronym: AIPHY
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 8, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Trial Details
NCT Number NCT05566002
Lead Sponsor Chinese Pulmonary Vascular Disease Research Group
Conditions
(from sponsor)		 Pulmonary Hypertension, Pulmonary Arterial Hypertension
Related terms Disease, Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov